The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R

Wilson, Wyndham H.; Gutierrez, Martin; O’Connor, Paula G.; Frankel, Stanley R.; Jaffe, Elaine S.; Chabner, Bruce A.; Grossbard, Michael L.

doi:10.1053/sonc.2002.30151

Cited by 68 publications

(30 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 There is evidence that rituximab can be added to combination chemotherapy regimens without significant increases in hematologic toxicity. [15][16][17][18] Adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) resulted in significantly longer overall and event-free survival times compared with CHOP alone in older patients with DLCL. 17 On this basis, we initiated a prospective trial in 1998 on the hypothesis that rituximab would be tolerated by patients early in their recovery from HCT and would have a favorable impact on the minimal residual disease that leads to relapse.…”

Section: Introductionmentioning

confidence: 99%

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Horwitz

Negrin

Blume

et al. 2004

Blood

187

109

View full text Add to dashboard Cite

Based on the favorable safety profile and the independent activity of rituximab in B-cell lymphoma, we evaluated its efficacy and toxicity after high-dose therapy (HDT) and autologous hematopoietic cell transplantation (HCT). Thirty-five patients with diffuse large cell (25 patients), mantle cell (3 patients), transformed (3 patients), or other (4 patients) subtypes of B-cell lymphoma received HDT followed by a purged autologous graft. The rituximab schedule was 4 weekly infusions (375 mg/m 2 ) starting at day 42 after HCT and, for patients 5 to 35, a second 4-week course 6 months after HCT. All planned therapy was completed in 29 patients. With 30 months' median follow-up, the 2-year event-free survival (EFS) rate was 83% and the overall survival (OS) rate was 88%. For 21 patients with relapsed or refractory large cell lymphoma, the EFS rate was 81% and the OS rate was 85%.

show abstract

Section: Introductionmentioning

confidence: 99%

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Horwitz

Negrin

Blume

et al. 2004

Blood

187

109

View full text Add to dashboard Cite

show abstract

“…Strategies designed to improve the anti-tumour effects of mAbs, by combining them with chemotherapy, have been tested in the laboratory as well as in the clinic (Czuczman, 2001;Wilson et al, 2002;Coiffier, 2003). Notably, the first rituximab immunochemotherapy trial, a Phase II clinical study of rituximab in combination with standard doses of cyclophosphamide, donoroubicin, vincristine and prednisone (CHOP) chemotherapy in patients with low-grade lymphoma demonstrated a 100% response rate, durable anti-tumour activity and excellent tolerability (Czuczman et al, 1999).…”

mentioning

confidence: 99%

Pro‐apoptotic therapy with the oligonucleotide Genasense^TM (oblimersen sodium) targeting Bcl‐2 protein expression enhances the biological anti‐tumour activity of rituximab

Ramanarayanan

Hernandez‐Ilizaliturri

Chanan‐Khan³

et al. 2004

Br J Haematol

View full text Add to dashboard Cite

SummaryNew strategies have evolved in the treatment of patients with nonHodgkin's lymphoma (NHL). Anti-sense oligonucleotides (ASO) and monoclonal antibody (mAb) therapy, though proven to be safe and effective, have not demonstrated to be curative when used as single agents. We tested an innovative combination strategy involving various mAbs and ASO against Bcl-2 (G3139) in aggressive preclinical models. G3139, under optimal transfection conditions, decreased the proliferation rate of lymphoma cells by 60-75% when compared with controls. In addition, apoptosis was demonstrated in Raji (25%) and DHL-4 cells (30%) treated with Genasense following downregulation of Bcl-2 protein. Downregulation of Bcl-2 by G3139 was associated with a higher degree of rituximab-associated, complement-mediated cytotoxicity and antibody dependent cellular cytotoxicity when compared with rituximab alonetreated controls. In vivo studies in severe combined immunodeficiency (SCID) mice clearly demonstrated synergistic activity between G3139 and rituximab. Treatment of lymphoma-bearing SCID mice with G3139 for two consecutive days prior to each rituximab dose resulted in better disease control and survival than treatment with either agent alone or controls. Our findings suggest that Bcl-2 downregulation by G3139, followed by the administration of rituximab is an efficient anti-tumour strategy associated with improved survival in lymphoma-bearing SCID mice.

show abstract

“…Since approval by the US Food and Drug Administration in 1997, more than 540,000 patients worldwide, mostly adults, have been treated with rituximab, primarily for Bcell NHL [21]. Despite initial fears that efficacy of rituximab might be limited to low-grade disease, significant improvements in overall survival and disease-free survival have been demonstrated with the addition of rituximab to various chemotherapy regimes in adult high-grade Burkitt and diffuse large B-cell lymphoma (DLBCL) without significant increase in toxicity [4,15,22,23]. In our cases, rituximab was well tolerated and no major side effects and toxicity were observed in patients.…”

Section: Discussionmentioning

confidence: 99%

Use of rituximab in three children with relapsed/refractory Burkitt lymphoma

et al. 2010

View full text Add to dashboard Cite

Monoclonal antibodies have provided new promise for patients with B-cell malignancies. Rituximab is a monoclonal antibody against B-lymphocytes that express CD20; it is used for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Very few data are available regarding the treatment of children with non-Hodgkin lymphoma with rituximab. In this article, we reported three children with primary refractory/relapsed B-cell-non-Hodgkin lymphoma, who were successfully treated with a combination of intensive chemotherapy protocol plus rituximab. In all three of our cases, the patients are still in complete remission. Our aim is to emphasize the importance of use of rituximab in the treatment of childhood B-cell non-Hodgkin lymphoma.

show abstract

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R

Cited by 68 publications

References 27 publications

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Pro‐apoptotic therapy with the oligonucleotide Genasense^TM (oblimersen sodium) targeting Bcl‐2 protein expression enhances the biological anti‐tumour activity of rituximab

Use of rituximab in three children with relapsed/refractory Burkitt lymphoma

Contact Info

Product

Resources

About

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R

Cited by 68 publications

References 27 publications

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Pro‐apoptotic therapy with the oligonucleotide GenasenseTM (oblimersen sodium) targeting Bcl‐2 protein expression enhances the biological anti‐tumour activity of rituximab

Use of rituximab in three children with relapsed/refractory Burkitt lymphoma

Contact Info

Product

Resources

About

Pro‐apoptotic therapy with the oligonucleotide Genasense^TM (oblimersen sodium) targeting Bcl‐2 protein expression enhances the biological anti‐tumour activity of rituximab